Opinion|Videos|March 21, 2025
Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment
Experts discuss the routine initiation of bridging therapy between leukapheresis and chimeric antigen receptor (CAR) T-cell infusion at their center; the pharmacist’s role in implementing this procedure; collaboration with the team on agent choice, dosage, and administration; and monitoring for disease control and adverse events as well as the observed impact of bridging therapy on outcomes post CAR T-cell therapy.
Advertisement
Video content above is prompted by the following:
At your center, is bridging therapy routinely initiated during the interval between leukapheresis and CAR T-cell infusion?
- If so, as a pharmacist, what is your role in implementing this procedure?
- With whom on the team do you communicate on choice of agent, dosage, administration frequency, and monitoring for disease control and adverse events?
- What impact of bridging therapy have you observed on outcomes post CAR T-cell therapy?
Advertisement
Related to this article
The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5